Latest research on Trazodone

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

Latest findings

The antidepressant types were divided into three categories: i) selective serotonin reuptake inhibitors including Citalopram, esCitalopram, fluoxetine, Paroxetine, and Sertraline, ii) newer antidepressants such as Bupropion, Venlafaxine, and Mirtazapine, and iii) older anti-depressants such as Amitriptyline, Clomipramine, Imipramine, Milnacipran, Nortriptyline, tianeptine, and Trazodone. [source, 2016]
Several pharmacological therapies for insomnia have been formulated, including benzodiazepine receptor antagonists (BzRAs) (eg, benzodiazepines and nonbenzodiazepine sedative-hypnotics, such as Zolpidem, Zaleplon, and Eszopiclone), Melatonin, Melatonin-receptor agonists, and various antidepressant medications including Quetiapine, Amitriptyline, Mirtazapine, and Trazodone. [source, 2016]
Of relevance, however, Ma et al20 compared the electroencephalographic (EEG) power spectral density profile of suvorexant with placebo, along with comparisons to gaboxadol 15 mg, Zolpidem 10 mg, and Trazodone 150 mg during REM and non-REM Sleep. [source, 2016]
Patients for whom complications have been encoded into depressive episode (ICD-10 code; F32) or recurrent depressive disorder (F33), and patients who were prescribed antidepressants (tricyclics, including Amitriptyline, Imipramine, Nortriptyline, Clomipramine, and amoxapine; tetracyclics, including maprotiline and mianserin; selective serotonin reuptake inhibitors [SSRIs], including Paroxetine, Fluvoxamine, and sertraline; serotonin Noradrenaline reuptake inhibitors [SNRIs], including Milnacipran and duloxetine; or others, including Trazodone, sulpiride, and Mirtazapine) were categorized in the depressive state group. [source, 2016]
This is in line with clinical data on the effect of Trazodone, suggesting that increasing 5-HT2A antagonisme improves Parkinson’s symptoms (Werneck et al., 2009) and has been demonstrated in an earlier version of the model before (Spiros et al., 2013). [source, 2016]
Another study tested fatty acids (Omega-3) in combination with antidepressants: Sertraline, tricyclic antidepressants, and Trazodone. [source, 2015]
According to drug groups evaluated, 5 groups of antidepressant medications were assessed including (1) selective serotonin reuptake inhibitors (SSRIs) (Escitalopram, Sertraline, citalopram, fluoxetine, Paroxetine); (2) tricyclic antidepressants (TCAs) (Amitriptyline, Imipramine, dezipramine.); (3) serotonin-norepinephrine reuptake inhibitors (SNRIs) (Venlafaxine, Duloxetine, sibutramine); (4) serotonin antagonist and reuptake inhibitors (SARIs) (Trazodone); and (5) noradrenergic and specific serotonergic antidepressants (NaSSAs) (Mirtazapine). [source, 2015]
In this group, Trazodone has been more studied regarding its effects on cardiovascular system. [source, 2015]
According to the case-control study by Weeke et al.,16 there was no association between the use of SARIs drugs such as Trazodone and cardiac-related death. [source, 2015]
In a case study by Service and Waring43 that described a woman who overdosed by acute ingestion of Trazodone, significant QT prolongation and delayed atrioventricular nodal conduction was developed after injecting Trazodone. [source, 2015]